uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT
Double Bond Pharmaceut AB, Uppsala, Sweden.
Minsk City Emergency Clin Hosp, Hlth Care Facil, Minsk, BELARUS.
Belarusian State Med Univ, Dept Neurol & Neurosurg, Minsk, BELARUS.
Belarusian State Univ, Res Inst Phys Chem Problems, Minsk, BELARUS.
Show others and affiliations
2019 (English)In: Neoplasma (Bratislava), ISSN 0028-2685, E-ISSN 1338-4317, Vol. 66, no 2, p. 288-293Article in journal (Refereed) Published
Abstract [en]

Glioma is the most common brain malignancy. Standard first-line therapy for glioma includes surgery, radiotherapy and systemic administration of temozolomide. However, temozolomide does not reach the brain in sufficient doses when administered orally and has poor efficiency in more than half of the patients. Strategies to improve the treatment of glial malignancies are therefore needed. We have recently developed a system (Temodex) for local administration of temozolomide by encapsulating the drug in a biologically inert matrix. Here, we assessed the effect of Temodex in combination with standard therapy in a small-scale clinical study. Since the efficacy of temozolomide therapy is known to depend on the methylation status of the O-6-methylguanine-DNA methyltransferase gene (MGMT) promoter, we also analyzed whether the effect of Temodex was influenced by the methylation status of MGMT. Our data show that the combination of standard therapy and Temodex was more efficient than standard therapy alone, promoting the overall patient survival by up to 33 weeks. Moreover, the efficacy of Temodex was not dependent on the methylation status of MGMT. Local Temodex administration in combination with standard therapy thereby emerges as a novel therapeutic option, with applicability that is independent on the methylation status of the MGMT promoter.

Place, publisher, year, edition, pages
AEPRESS SRO , 2019. Vol. 66, no 2, p. 288-293
Keywords [en]
glioma, Temodex, temozolomide, MGTM, methylation
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-383209DOI: 10.4149/neo_2018_180613N393ISI: 000465160800016PubMedID: 30569719OAI: oai:DiVA.org:uu-383209DiVA, id: diva2:1315061
Available from: 2019-05-10 Created: 2019-05-10 Last updated: 2019-05-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Pejler, Gunnar

Search in DiVA

By author/editor
Pejler, Gunnar
By organisation
Department of Medical Biochemistry and Microbiology
In the same journal
Neoplasma (Bratislava)
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 28 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf